Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Terminates Development Of Aveo Antibody

Executive Summary

Novartis has walked away from Aveo’s cachexia candidate after a turbulent week in the development of the antibody program, three years after paying $15m for development and commercialization rights.

You may also be interested in...

Aveo Eyes Role For Tivozanib In US Kidney Cancer Market, Against The Odds

In the Phase III TIVO-3 study, tivozanib is associated with a trend toward adverse survival and trial has missing data issues.

Latest R&D Deal Builds China Antibody Interest, Expertise

To promote both the development of innovative therapeutic antibodies from research originating in China and technology transfer, the Institute Pasteur of Shanghai and MRC Technology are collaborating to speed antibody R&D and scouting licensing opportunities with local pharmas, adding to a string of deals indicative of China’s increasing expertise and interest in the sector.

Aveo Licenses Tricky Tivozanib To EUSA In Europe

If Aveo Oncology's lead cancer drug candidate tivozanib was a cat, it would be on its eighth out of nine lives by now, the latest of which involves an ex-US partnership with EUSA Pharma that offers a small $2.5m upfront payment, but potentially lucrative milestone fees totaling as much as $394m.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts